Noting Veeva’s (NYSE:VEEV)
“enviable financial model,” Citi analyst Tyler Radke starts the company
with a Buy rating and a $265 price target, a 31% upside.
Radke notes the 20-30% Y/Y revenue growth and strong profitability, which should help drive strong returns for Veeva.
The analyst mentions that Veeva’s SaaS suite targets the “lucrative” life sciences market.
Radke compares Veeva to Salesforce’s growth story, but he sees stronger profits for Veeva.
https://seekingalpha.com/news/3581061-veeva-gets-street-high-price-target
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.